Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent...
Saved in:
| Published in | Nature immunology Vol. 22; no. 12; pp. 1503 - 1514 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Nature Publishing Group US
01.12.2021
Nature Publishing Group Nature Research, Springer Nature |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance.
Krebs and colleagues identify multiple mAbs that recognize either the RBD or the NTD of SARS-CoV-2 spike protein that have potent cross-neutralizing activities against variants of concern. Combinatorial mAb cocktails have complementary effects on viral neutralization and Fc effector functions and can protect against SARS-CoV-2 escape mutants. |
|---|---|
| AbstractList | Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance. Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance. Krebs and colleagues identify multiple mAbs that recognize either the RBD or the NTD of SARS-CoV-2 spike protein that have potent cross-neutralizing activities against variants of concern. Combinatorial mAb cocktails have complementary effects on viral neutralization and Fc effector functions and can protect against SARS-CoV-2 escape mutants. Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance.Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance. Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance. Krebs and colleagues identify multiple mAbs that recognize either the RBD or the NTD of SARS-CoV-2 spike protein that have potent cross-neutralizing activities against variants of concern. Combinatorial mAb cocktails have complementary effects on viral neutralization and Fc effector functions and can protect against SARS-CoV-2 escape mutants. AbstractPrevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance. |
| Audience | Academic |
| Author | Krebs, Shelly J. Hatziioannou, Theodora Polonis, Victoria R. Townsley, Samantha M. Paquin-Proulx, Dominic Chang, William C. Thomas, Paul V. Kwong, Peter D. Jackson, Nathaniel D. Doranz, Benjamin J. Jian, Ningbo Peterson, Caroline E. Dussupt, Vincent Slike, Bonnie M. Teng, I-Ting Gromowski, Gregory D. Hajduczki, Agnes Schmidt, Fabian Choe, Misook Swafford, Isabella Joyce, M. Gordon Selverian, Christopher N. Lal, Kerri G. Chen, Wei-Hung Mores, Christopher N. Michael, Nelson L. Rees, Phyllis A. Smith, Clayton J. Wieczorek, Lindsay Zemil, Michelle Rolland, Morgane Modjarrad, Kayvon Tran, Ursula Donofrio, Gina C. Zaky, Weam I. Ahmed, Aslaa Zhou, Tongqing Tritsch, Sarah R. Martinez, Elizabeth J. Bieniasz, Paul D. Rutkowska, Magdalena Currier, Jeffrey R. Sankhala, Rajeshwer S. Davidson, Edgar Mendez-Rivera, Letzibeth Reiley, William W. |
| Author_xml | – sequence: 1 givenname: Vincent orcidid: 0000-0002-8579-6356 surname: Dussupt fullname: Dussupt, Vincent organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 2 givenname: Rajeshwer S. surname: Sankhala fullname: Sankhala, Rajeshwer S. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 3 givenname: Letzibeth surname: Mendez-Rivera fullname: Mendez-Rivera, Letzibeth organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 4 givenname: Samantha M. surname: Townsley fullname: Townsley, Samantha M. organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 5 givenname: Fabian surname: Schmidt fullname: Schmidt, Fabian organization: Laboratory of Retrovirology, The Rockefeller University – sequence: 6 givenname: Lindsay surname: Wieczorek fullname: Wieczorek, Lindsay organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 7 givenname: Kerri G. surname: Lal fullname: Lal, Kerri G. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 8 givenname: Gina C. surname: Donofrio fullname: Donofrio, Gina C. organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 9 givenname: Ursula surname: Tran fullname: Tran, Ursula organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 10 givenname: Nathaniel D. orcidid: 0000-0002-9654-6926 surname: Jackson fullname: Jackson, Nathaniel D. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 11 givenname: Weam I. surname: Zaky fullname: Zaky, Weam I. organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 12 givenname: Michelle orcidid: 0000-0002-1700-6658 surname: Zemil fullname: Zemil, Michelle organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 13 givenname: Sarah R. surname: Tritsch fullname: Tritsch, Sarah R. organization: Milken Institute School of Public Health, The George Washington University – sequence: 14 givenname: Wei-Hung surname: Chen fullname: Chen, Wei-Hung organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 15 givenname: Elizabeth J. surname: Martinez fullname: Martinez, Elizabeth J. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 16 givenname: Aslaa orcidid: 0000-0003-3093-4982 surname: Ahmed fullname: Ahmed, Aslaa organization: Viral Diseases Branch, Walter Reed Army Institute of Research – sequence: 17 givenname: Misook surname: Choe fullname: Choe, Misook organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 18 givenname: William C. orcidid: 0000-0003-4967-6426 surname: Chang fullname: Chang, William C. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 19 givenname: Agnes surname: Hajduczki fullname: Hajduczki, Agnes organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 20 givenname: Ningbo surname: Jian fullname: Jian, Ningbo organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 21 givenname: Caroline E. surname: Peterson fullname: Peterson, Caroline E. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 22 givenname: Phyllis A. surname: Rees fullname: Rees, Phyllis A. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 23 givenname: Magdalena surname: Rutkowska fullname: Rutkowska, Magdalena organization: Laboratory of Retrovirology, The Rockefeller University – sequence: 24 givenname: Bonnie M. orcidid: 0000-0003-4132-4637 surname: Slike fullname: Slike, Bonnie M. organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 25 givenname: Christopher N. orcidid: 0000-0002-1047-4336 surname: Selverian fullname: Selverian, Christopher N. organization: Integral Molecular – sequence: 26 givenname: Isabella orcidid: 0000-0001-8638-2772 surname: Swafford fullname: Swafford, Isabella organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 27 givenname: I-Ting surname: Teng fullname: Teng, I-Ting organization: Vaccine Research Center, NIAID, NIH – sequence: 28 givenname: Paul V. surname: Thomas fullname: Thomas, Paul V. organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 29 givenname: Tongqing orcidid: 0000-0002-3935-4637 surname: Zhou fullname: Zhou, Tongqing organization: Vaccine Research Center, NIAID, NIH – sequence: 30 givenname: Clayton J. surname: Smith fullname: Smith, Clayton J. organization: NCI, NIH – sequence: 31 givenname: Jeffrey R. orcidid: 0000-0002-5696-0268 surname: Currier fullname: Currier, Jeffrey R. organization: Viral Diseases Branch, Walter Reed Army Institute of Research – sequence: 32 givenname: Peter D. orcidid: 0000-0003-3560-232X surname: Kwong fullname: Kwong, Peter D. organization: Vaccine Research Center, NIAID, NIH – sequence: 33 givenname: Morgane orcidid: 0000-0003-3650-8490 surname: Rolland fullname: Rolland, Morgane organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 34 givenname: Edgar surname: Davidson fullname: Davidson, Edgar organization: Integral Molecular – sequence: 35 givenname: Benjamin J. orcidid: 0000-0002-8245-3083 surname: Doranz fullname: Doranz, Benjamin J. organization: Integral Molecular – sequence: 36 givenname: Christopher N. orcidid: 0000-0001-6678-9049 surname: Mores fullname: Mores, Christopher N. organization: Milken Institute School of Public Health, The George Washington University – sequence: 37 givenname: Theodora surname: Hatziioannou fullname: Hatziioannou, Theodora organization: Laboratory of Retrovirology, The Rockefeller University – sequence: 38 givenname: William W. surname: Reiley fullname: Reiley, William W. organization: Trudeau Institute – sequence: 39 givenname: Paul D. orcidid: 0000-0002-2368-3719 surname: Bieniasz fullname: Bieniasz, Paul D. organization: Laboratory of Retrovirology, The Rockefeller University, Howard Hughes Medical Institute, The Rockefeller University – sequence: 40 givenname: Dominic orcidid: 0000-0003-1407-3414 surname: Paquin-Proulx fullname: Paquin-Proulx, Dominic organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 41 givenname: Gregory D. surname: Gromowski fullname: Gromowski, Gregory D. organization: Viral Diseases Branch, Walter Reed Army Institute of Research – sequence: 42 givenname: Victoria R. surname: Polonis fullname: Polonis, Victoria R. organization: U.S. Military HIV Research Program, Walter Reed Army Institute of Research – sequence: 43 givenname: Nelson L. orcidid: 0000-0001-5882-5548 surname: Michael fullname: Michael, Nelson L. organization: Center of Infectious Disease Research, Walter Reed Army Institute of Research – sequence: 44 givenname: Kayvon surname: Modjarrad fullname: Modjarrad, Kayvon organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research – sequence: 45 givenname: M. Gordon orcidid: 0000-0002-6808-7232 surname: Joyce fullname: Joyce, M. Gordon email: gjoyce@eidresearch.org organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine – sequence: 46 givenname: Shelly J. orcidid: 0000-0003-1136-1760 surname: Krebs fullname: Krebs, Shelly J. email: skrebs@hivresearch.org organization: Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Henry M. Jackson Foundation for the Advancement of Military Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34716452$$D View this record in MEDLINE/PubMed https://www.osti.gov/servlets/purl/1837258$$D View this record in Osti.gov |
| BookMark | eNp9kkuP0zAUhSM0iHnAH2CBItjAIoPtOI69GamqeIxUCWkKbC3HcToeJb4lTgrtr-e2nQcdoVEWiZzvHF8fn9PkKEBwSfKaknNKcvkxclookhFGM0KJkNnmWXJCC6Yypqg4uv8m8jg5jfGGEMpLwV8kxzkvqeAFO0m6GfzOaogu9SFd-RWkyx4GZwcPITWhToMbh960fmP2S7aHGNP55GqeTeFnxtKV6b0JQ0yrddpBANtCMC1qB19BvU4tdJUPO3V8mTxvTBvdq9v3WfLj86fv06_Z7NuXy-lkllkh5JAxpxQTVjhura2caWzJqkKVOaOqqp2iFakUqXkjmc0Fr5RrGloWShBmrcplfpZc7H2XY9W52rqwPYNe9r4z_VqD8frwT_DXegErLQVnjDM0eLs3gDh4Ha3HSK4thIDJaCrzkhXbXd7f7tLDr9HFQXc-Wte2JjgYo2Z4O0QWlJSIvnuE3sDYY05ICVKUJcH5H6iFaZ32oQEczm5N9URIrjgyHKnz_1D41K7zOKNrPK4fCD4cCJAZ3J9hYcYY9eX86pB9829y95HdNQYBuQd2RehdozGc3e3iFL7VlOhtOfW-nBrLqXfl1BuUskfSO_cnRfleFBEOC9c_JPeE6i_71vZl |
| CitedBy_id | crossref_primary_10_1021_acsnano_4c00809 crossref_primary_10_1021_acs_nanolett_2c04270 crossref_primary_10_1073_pnas_2314193120 crossref_primary_10_3390_vaccines11010042 crossref_primary_10_1016_j_bj_2023_02_007 crossref_primary_10_3390_vaccines11061014 crossref_primary_10_1128_jvi_01596_22 crossref_primary_10_4049_jimmunol_2300675 crossref_primary_10_3389_fviro_2023_1128253 crossref_primary_10_1128_spectrum_03562_22 crossref_primary_10_1172_JCI157416 crossref_primary_10_1126_scitranslmed_adf4549 crossref_primary_10_2147_IJN_S463546 crossref_primary_10_1111_imr_13431 crossref_primary_10_1016_j_celrep_2022_110862 crossref_primary_10_3390_vaccines10050717 crossref_primary_10_1111_nyas_14915 crossref_primary_10_1080_19420862_2022_2031483 crossref_primary_10_1126_scitranslmed_adq5720 crossref_primary_10_1073_pnas_2217590120 crossref_primary_10_1016_j_str_2023_11_015 crossref_primary_10_3389_fimmu_2022_901217 crossref_primary_10_1021_acs_analchem_4c03574 crossref_primary_10_1038_s41467_022_35456_2 crossref_primary_10_3390_vaccines10050772 crossref_primary_10_1016_j_ymthe_2022_04_001 crossref_primary_10_7554_eLife_74060 crossref_primary_10_1126_sciadv_adk4920 crossref_primary_10_1038_s41565_022_01174_5 crossref_primary_10_1016_j_immuni_2022_04_003 crossref_primary_10_1080_22221751_2024_2447615 crossref_primary_10_1093_procel_pwad040 crossref_primary_10_1126_sciimmunol_abp9312 crossref_primary_10_1016_j_ebiom_2023_104683 crossref_primary_10_1016_j_isci_2024_110624 crossref_primary_10_3390_v16060900 crossref_primary_10_1016_j_it_2024_06_003 crossref_primary_10_1038_s41467_023_44265_0 crossref_primary_10_1111_imr_13084 crossref_primary_10_1016_j_celrep_2023_112014 crossref_primary_10_1038_s41467_023_36106_x |
| Cites_doi | 10.1126/science.abd2321 10.1016/j.cell.2021.03.029 10.1371/journal.pmed.0030237 10.1016/j.chom.2021.04.005 10.1038/s41586-020-2852-1 10.1107/S0907444904019158 10.1038/s41586-020-2380-z 10.1111/imm.12323 10.1126/science.abe3354 10.1126/science.abc6952 10.1084/jem.20201993 10.1126/science.abb7269 10.1084/jem.20201181 10.1038/s41586-021-03777-9 10.1056/NEJMoa2109682 10.1126/science.abd0831 10.1016/j.cell.2020.05.025 10.1073/pnas.0602606103 10.1038/s41564-021-00972-2 10.7554/eLife.61312 10.1128/JVI.78.19.10628-10635.2004 10.1038/s41467-020-19891-7 10.1016/j.jsb.2012.09.006 10.1126/science.abd0827 10.1126/science.abf4830 10.1128/JVI.01708-08 10.1126/scitranslmed.abf1906 10.1016/j.cell.2020.02.052 10.1038/s41422-021-00497-7 10.1126/science.abc7520 10.1016/j.jim.2019.07.002 10.1016/j.celrep.2021.109450 10.1016/j.chom.2021.03.005 10.1038/s41591-019-0746-2 10.1016/j.cell.2021.02.032 10.1016/j.cell.2021.03.028 10.1038/s41467-019-10897-4 10.1016/j.immuni.2020.07.020 10.1016/j.cell.2021.02.035 10.1038/s41586-020-2571-7 10.1126/science.abg5268 10.1038/s41586-020-2456-9 10.1038/s41586-021-03807-6 10.1016/j.cell.2021.02.026 10.1038/s41598-018-34171-7 10.1016/j.jim.2010.12.016 10.1126/science.abd0826 10.1038/s41586-020-2548-6 10.1038/s41590-020-0778-2 10.1016/j.xcrm.2021.100405 10.1016/S0076-6879(97)76066-X 10.1016/j.immuni.2021.08.015 10.1126/science.abh1766 10.1002/jcc.20084 10.1074/jbc.M116.767749 10.1128/JCM.00527-21 10.1038/nmeth.4169 10.1001/jama.2021.0202 10.1016/j.jim.2012.09.007 10.1016/j.celrep.2020.108322 10.1107/S0021889807021206 10.1038/s41591-021-01294-w 10.1107/S0907444909011548 10.1038/s41422-021-00487-9 10.1101/2020.03.15.992883 10.1101/2021.05.09.443331 10.1101/2021.03.24.436523 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). COPYRIGHT 2021 Nature Publishing Group The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: COPYRIGHT 2021 Nature Publishing Group – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| CorporateAuthor | Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS) |
| CorporateAuthor_xml | – name: Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS) |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7QP 7QR 7T5 7TK 7TM 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7N M7P P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 OIOZB OTOTI 5PM |
| DOI | 10.1038/s41590-021-01068-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale in Context: Science ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic OSTI.GOV - Hybrid OSTI.GOV PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Public Health ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1529-2916 |
| EndPage | 1514 |
| ExternalDocumentID | PMC8642242 1837258 A684947534 34716452 10_1038_s41590_021_01068_z |
| Genre | Research Support, U.S. Gov't, P.H.S Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GrantInformation_xml | – fundername: United States Department of Defense | United States Army | Army Medical Command | Walter Reed Army Institute of Research (WRAIR) grantid: W81XWH-18-2-0040; W81XWH-18-2-0040 funderid: https://doi.org/10.13039/100010203 – fundername: U.S. Department of Defense (United States Department of Defense) grantid: W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040 funderid: https://doi.org/10.13039/100000005 – fundername: U.S. Department of Health & Human Services | National Institutes of Health (NIH) grantid: HHSN 75N93019C00073; R01AI78788; R01AI50111 funderid: https://doi.org/10.13039/100000002 – fundername: ; grantid: W81XWH-18-2-0040; W81XWH-18-2-0040 – fundername: ; grantid: HHSN 75N93019C00073; R01AI78788; R01AI50111 – fundername: ; grantid: W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040; W81XWH-18-2-0040 |
| GroupedDBID | --- .55 0R~ 123 29M 2FS 36B 39C 3V. 4.4 53G 5BI 5RE 70F 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8R4 8R5 AAEEF AAHBH AARCD AAYZH AAZLF ABAWZ ABDBF ABJNI ABLJU ABNNU ABOCM ABUWG ACBWK ACGFS ACIWK ACPRK ACRPL ACUHS ADBBV ADNMO AENEX AEUYN AFBBN AFKRA AFRAH AFSHS AGAYW AGGDT AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ AIYXT ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ARMCB ASPBG AVWKF AXYYD AZFZN BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI C6C CCPQU CS3 DB5 DU5 EAD EAP EAS EBS EE. EJD EMB EMK EMOBN ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA HCIFZ HMCUK HVGLF HZ~ IAO IHR INH INR ISR ITC L-9 LK8 M1P M7P N9A NNMJJ O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RNT RNTTT SHXYY SIXXV SNYQT SOJ SV3 TAOOD TBHMF TDRGL TSG TUS UKHRP WH7 X7M Y6R ZXP AAYXX ABFSG ACSTC AEZWR AFANA AFHIU AHWEU AIXLP ALPWD ATHPR CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NFIDA NPM AEIIB PMFND 7QP 7QR 7T5 7TK 7TM 7U9 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS PUEGO RC3 7X8 AADEA AADWK AAEXX AAJMP AAPBV AAYJO ABEEJ ABGIJ ABPTK ABVXF ACBMV ACBRV ACBYP ACIGE ACTTH ACVWB ADMDM ADQMX ADZGE AEDAW AEFTE AGEZK AGGBP AHGBK AJDOV NYICJ OIOZB OTOTI ZA5 5PM |
| ID | FETCH-LOGICAL-c668t-2e9926c6e4cccbeafc72b5973219bde91b0b90d4f82c364b9eff1759602cc9383 |
| IEDL.DBID | 7X7 |
| ISSN | 1529-2908 1529-2916 |
| IngestDate | Thu Aug 21 14:33:20 EDT 2025 Fri May 19 01:41:24 EDT 2023 Fri Jul 11 14:34:53 EDT 2025 Sat Aug 23 14:48:27 EDT 2025 Tue Jun 17 20:21:18 EDT 2025 Tue Jun 10 20:41:20 EDT 2025 Fri Jun 27 04:01:31 EDT 2025 Thu Apr 03 07:01:01 EDT 2025 Tue Jul 01 01:02:33 EDT 2025 Thu Apr 24 23:11:50 EDT 2025 Fri Feb 21 02:39:03 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | 2021. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c668t-2e9926c6e4cccbeafc72b5973219bde91b0b90d4f82c364b9eff1759602cc9383 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 National Cancer Institute (NCI) AC02-06CH11357; W81XWH-18-2-0040; R01AI50111; R01AI78788; HHSN 75N93019C00073; S10OD021527; HSSN261200800001E USDOE Office of Science (SC) Vaccine Research Center National Institutes of Health (NIH) USDOD |
| ORCID | 0000-0002-6808-7232 0000-0002-9654-6926 0000-0002-8579-6356 0000-0003-4132-4637 0000-0002-5696-0268 0000-0001-6678-9049 0000-0002-3935-4637 0000-0002-8245-3083 0000-0003-4967-6426 0000-0003-3093-4982 0000-0002-1700-6658 0000-0003-1407-3414 0000-0003-1136-1760 0000-0002-2368-3719 0000-0002-1047-4336 0000-0003-3560-232X 0000-0001-5882-5548 0000-0001-8638-2772 0000-0003-3650-8490 0000000330934982 0000000296546926 0000000311361760 0000000217006658 0000000239354637 000000033560232X 0000000314073414 0000000158825548 0000000349676426 0000000223683719 0000000285796356 0000000268087232 0000000256960268 0000000186382772 0000000210474336 0000000166789049 0000000341324637 0000000336508490 0000000282453083 |
| OpenAccessLink | https://www.nature.com/articles/s41590-021-01068-z |
| PMID | 34716452 |
| PQID | 2605770175 |
| PQPubID | 45782 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8642242 osti_scitechconnect_1837258 proquest_miscellaneous_2590085107 proquest_journals_2605770175 gale_infotracmisc_A684947534 gale_infotracacademiconefile_A684947534 gale_incontextgauss_ISR_A684947534 pubmed_primary_34716452 crossref_citationtrail_10_1038_s41590_021_01068_z crossref_primary_10_1038_s41590_021_01068_z springer_journals_10_1038_s41590_021_01068_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-12-01 |
| PublicationDateYYYYMMDD | 2021-12-01 |
| PublicationDate_xml | – month: 12 year: 2021 text: 2021-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Nature immunology |
| PublicationTitleAbbrev | Nat Immunol |
| PublicationTitleAlternate | Nat Immunol |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group US Nature Publishing Group Nature Research, Springer Nature |
| Publisher_xml | – name: Nature Publishing Group US – name: Nature Publishing Group – name: Nature Research, Springer Nature |
| References | Sholukh (CR21) 2021; 59 Oladunni (CR34) 2020; 11 Planas (CR10) 2021; 596 Chen (CR9) 2021; 27 Yuan (CR49) 2020; 369 Sun (CR44) 2021; 31 Tomaras (CR51) 2008; 82 Strong (CR59) 2006; 103 Hsieh (CR11) 2020; 369 Atyeo (CR47) 2020; 53 Winkler (CR33) 2020; 21 Ackerman (CR55) 2011; 366 Suryadevara (CR22) 2021; 184 Lo (CR35) 2017; 292 McCoy (CR60) 2007; 40 Rogers (CR13) 2020; 369 Fischinger (CR56) 2019; 473 McCallum (CR7) 2021; 184 Otwinowski, Minor (CR63) 1997; 276 Hansen (CR41) 2020; 369 Gottlieb (CR1) 2021; 325 Robbiani (CR14) 2020; 584 Dong (CR4) 2021; 6 Moore (CR52) 2004; 78 Schmidt (CR67) 2020; 217 Cerutti (CR8) 2021; 29 Voss (CR27) 2021; 372 Hoffmann (CR6) 2020; 181 Punjani, Rubinstein, Fleet, Brubaker (CR65) 2017; 14 Ju (CR12) 2020; 584 Jones (CR43) 2021; 13 Andreano (CR42) 2021; 184 Chi (CR26) 2020; 369 Zhou (CR38) 2019; 10 Weisblum (CR36) 2020; 9 Emsley, Cowtan (CR61) 2004; 60 Cao (CR17) 2020; 182 Yuan (CR32) 2020; 368 Dussupt (CR39) 2020; 26 Dejnirattisai (CR30) 2021; 184 Brown (CR50) 2012; 386 ter Meulen (CR57) 2006; 3 Davidson, Doranz (CR58) 2014; 143 CR19 CR18 Winkler (CR23) 2021; 184 Ullah (CR25) 2021; 54 Zhou (CR54) 2020; 33 Gorman (CR48) 2021; 2 Kirchdoerfer (CR53) 2018; 8 Martinez (CR5) 2021; 36 O’Brien (CR2) 2021; 385 Tortorici (CR16) 2020; 370 Liu (CR20) 2020; 584 Baum (CR37) 2020; 369 Barnes (CR29) 2020; 588 Wang (CR40) 2021; 373 CR28 Zost (CR15) 2020; 584 Schafer (CR24) 2021; 218 Pettersen (CR66) 2004; 25 Starr (CR3) 2021; 597 Adams, Mustyakimov, Afonine, Langan (CR62) 2009; 65 Rappazzo (CR46) 2021; 371 Yan (CR45) 2021; 31 Scheres (CR64) 2012; 180 Liu (CR31) 2021; 29 ES Winkler (1068_CR23) 2021; 184 H Liu (1068_CR31) 2021; 29 H Zhou (1068_CR38) 2019; 10 R Yan (1068_CR45) 2021; 31 V Dussupt (1068_CR39) 2020; 26 Z Otwinowski (1068_CR63) 1997; 276 MA Tortorici (1068_CR16) 2020; 370 ES Winkler (1068_CR33) 2020; 21 I Ullah (1068_CR25) 2021; 54 A Schafer (1068_CR24) 2021; 218 A Baum (1068_CR37) 2020; 369 AM Sholukh (1068_CR21) 2021; 59 Y Sun (1068_CR44) 2021; 31 SJ Zost (1068_CR15) 2020; 584 SH Scheres (1068_CR64) 2012; 180 MP O’Brien (1068_CR2) 2021; 385 1068_CR28 EF Pettersen (1068_CR66) 2004; 25 G Cerutti (1068_CR8) 2021; 29 N Suryadevara (1068_CR22) 2021; 184 MJ Gorman (1068_CR48) 2021; 2 E Davidson (1068_CR58) 2014; 143 FS Oladunni (1068_CR34) 2020; 11 DR Martinez (1068_CR5) 2021; 36 E Andreano (1068_CR42) 2021; 184 TN Starr (1068_CR3) 2021; 597 MJ Moore (1068_CR52) 2004; 78 B Ju (1068_CR12) 2020; 584 S Fischinger (1068_CR56) 2019; 473 RE Chen (1068_CR9) 2021; 27 X Chi (1068_CR26) 2020; 369 M Lo (1068_CR35) 2017; 292 P Emsley (1068_CR61) 2004; 60 ME Ackerman (1068_CR55) 2011; 366 L Liu (1068_CR20) 2020; 584 EP Brown (1068_CR50) 2012; 386 M Strong (1068_CR59) 2006; 103 A Punjani (1068_CR65) 2017; 14 F Schmidt (1068_CR67) 2020; 217 TF Rogers (1068_CR13) 2020; 369 RN Kirchdoerfer (1068_CR53) 2018; 8 CO Barnes (1068_CR29) 2020; 588 Y Cao (1068_CR17) 2020; 182 T Zhou (1068_CR54) 2020; 33 J Dong (1068_CR4) 2021; 6 L Wang (1068_CR40) 2021; 373 J Hansen (1068_CR41) 2020; 369 W Dejnirattisai (1068_CR30) 2021; 184 D Planas (1068_CR10) 2021; 596 CG Rappazzo (1068_CR46) 2021; 371 GD Tomaras (1068_CR51) 2008; 82 CL Hsieh (1068_CR11) 2020; 369 DF Robbiani (1068_CR14) 2020; 584 M McCallum (1068_CR7) 2021; 184 M Yuan (1068_CR49) 2020; 369 PD Adams (1068_CR62) 2009; 65 RL Gottlieb (1068_CR1) 2021; 325 BE Jones (1068_CR43) 2021; 13 M Hoffmann (1068_CR6) 2020; 181 WN Voss (1068_CR27) 2021; 372 M Yuan (1068_CR32) 2020; 368 C Atyeo (1068_CR47) 2020; 53 J ter Meulen (1068_CR57) 2006; 3 AJ McCoy (1068_CR60) 2007; 40 Y Weisblum (1068_CR36) 2020; 9 1068_CR19 1068_CR18 |
| References_xml | – volume: 369 start-page: 1119 year: 2020 end-page: 1123 ident: CR49 article-title: Structural basis of a shared antibody response to SARS-CoV-2 publication-title: Science doi: 10.1126/science.abd2321 – volume: 184 start-page: 2316 year: 2021 end-page: 2331 ident: CR22 article-title: Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein publication-title: Cell doi: 10.1016/j.cell.2021.03.029 – volume: 3 start-page: e237 year: 2006 ident: CR57 article-title: Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants publication-title: PLoS Med. doi: 10.1371/journal.pmed.0030237 – volume: 29 start-page: 806 year: 2021 end-page: 818 ident: CR31 article-title: A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.04.005 – volume: 588 start-page: 682 year: 2020 end-page: 687 ident: CR29 article-title: SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies publication-title: Nature doi: 10.1038/s41586-020-2852-1 – volume: 60 start-page: 2126 year: 2004 end-page: 2132 ident: CR61 article-title: Coot: model-building tools for molecular graphics publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444904019158 – volume: 584 start-page: 115 year: 2020 end-page: 119 ident: CR12 article-title: Human neutralizing antibodies elicited by SARS-CoV-2 infection publication-title: Nature doi: 10.1038/s41586-020-2380-z – volume: 143 start-page: 13 year: 2014 end-page: 20 ident: CR58 article-title: A high-throughput shotgun mutagenesis approach to mapping B cell antibody epitopes publication-title: Immunology doi: 10.1111/imm.12323 – volume: 370 start-page: 950 year: 2020 end-page: 957 ident: CR16 article-title: Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms publication-title: Science doi: 10.1126/science.abe3354 – volume: 369 start-page: 650 year: 2020 end-page: 655 ident: CR26 article-title: A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2 publication-title: Science doi: 10.1126/science.abc6952 – volume: 218 start-page: e20201993 year: 2021 ident: CR24 article-title: Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo publication-title: J. Exp. Med. doi: 10.1084/jem.20201993 – volume: 368 start-page: 630 year: 2020 end-page: 633 ident: CR32 article-title: A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV publication-title: Science doi: 10.1126/science.abb7269 – volume: 217 start-page: e20201181 year: 2020 ident: CR67 article-title: Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses publication-title: J. Exp. Med. doi: 10.1084/jem.20201181 – volume: 596 start-page: 276 year: 2021 end-page: 280 ident: CR10 article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization publication-title: Nature doi: 10.1038/s41586-021-03777-9 – volume: 385 start-page: 1184 year: 2021 end-page: 1195 ident: CR2 article-title: Subcutaneous REGEN-COV antibody combination to prevent COVID-19 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2109682 – volume: 369 start-page: 1014 year: 2020 end-page: 1018 ident: CR37 article-title: Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies publication-title: Science doi: 10.1126/science.abd0831 – volume: 182 start-page: 73 year: 2020 end-page: 84 ident: CR17 article-title: Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells publication-title: Cell doi: 10.1016/j.cell.2020.05.025 – volume: 103 start-page: 8060 year: 2006 end-page: 8065 ident: CR59 article-title: Toward the structural genomics of complexes: crystal structure of a PE/PPE protein complex from publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0602606103 – volume: 6 start-page: 1233 year: 2021 end-page: 1244 ident: CR4 article-title: Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail publication-title: Nat. Microbiol. doi: 10.1038/s41564-021-00972-2 – ident: CR19 – volume: 9 start-page: e61312 year: 2020 ident: CR36 article-title: Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants publication-title: Elife doi: 10.7554/eLife.61312 – volume: 78 start-page: 10628 year: 2004 end-page: 10635 ident: CR52 article-title: Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2 publication-title: J. Virol. doi: 10.1128/JVI.78.19.10628-10635.2004 – volume: 11 year: 2020 ident: CR34 article-title: Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice publication-title: Nat. Commun. doi: 10.1038/s41467-020-19891-7 – volume: 180 start-page: 519 year: 2012 end-page: 530 ident: CR64 article-title: RELION: implementation of a Bayesian approach to cryo-EM structure determination publication-title: J. Struct. Biol. doi: 10.1016/j.jsb.2012.09.006 – volume: 369 start-page: 1010 year: 2020 end-page: 1014 ident: CR41 article-title: Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail publication-title: Science doi: 10.1126/science.abd0827 – volume: 371 start-page: 823 year: 2021 end-page: 829 ident: CR46 article-title: Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody publication-title: Science doi: 10.1126/science.abf4830 – volume: 82 start-page: 12449 year: 2008 end-page: 12463 ident: CR51 article-title: Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia publication-title: J. Virol. doi: 10.1128/JVI.01708-08 – volume: 13 start-page: eabf1906 year: 2021 ident: CR43 article-title: The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abf1906 – volume: 181 start-page: 271 year: 2020 end-page: 280 ident: CR6 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 31 start-page: 597 year: 2021 end-page: 600 ident: CR44 article-title: Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms publication-title: Cell Res. doi: 10.1038/s41422-021-00497-7 – volume: 369 start-page: 956 year: 2020 end-page: 963 ident: CR13 article-title: Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model publication-title: Science doi: 10.1126/science.abc7520 – volume: 473 start-page: 112630 year: 2019 ident: CR56 article-title: A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2019.07.002 – volume: 36 start-page: 109450 year: 2021 ident: CR5 article-title: Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice publication-title: Cell Rep. doi: 10.1016/j.celrep.2021.109450 – volume: 29 start-page: 819 year: 2021 end-page: 833 ident: CR8 article-title: Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.005 – volume: 26 start-page: 228 year: 2020 end-page: 235 ident: CR39 article-title: Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor publication-title: Nat. Med. doi: 10.1038/s41591-019-0746-2 – volume: 184 start-page: 2183 year: 2021 end-page: 2200 ident: CR30 article-title: The antigenic anatomy of SARS-CoV-2 receptor binding domain publication-title: Cell doi: 10.1016/j.cell.2021.02.032 – ident: CR18 – volume: 184 start-page: 2332 year: 2021 end-page: 2347 ident: CR7 article-title: N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 publication-title: Cell doi: 10.1016/j.cell.2021.03.028 – volume: 10 year: 2019 ident: CR38 article-title: Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein publication-title: Nat. Commun. doi: 10.1038/s41467-019-10897-4 – volume: 53 start-page: 524 year: 2020 end-page: 532 ident: CR47 article-title: Distinct early serological signatures track with SARS-CoV-2 survival publication-title: Immunity doi: 10.1016/j.immuni.2020.07.020 – volume: 184 start-page: 1821 year: 2021 end-page: 1835 ident: CR42 article-title: Extremely potent human monoclonal antibodies from COVID-19 convalescent patients publication-title: Cell doi: 10.1016/j.cell.2021.02.035 – volume: 584 start-page: 450 year: 2020 end-page: 456 ident: CR20 article-title: Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike publication-title: Nature doi: 10.1038/s41586-020-2571-7 – volume: 372 start-page: 1108 year: 2021 end-page: 1112 ident: CR27 article-title: Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes publication-title: Science doi: 10.1126/science.abg5268 – volume: 584 start-page: 437 year: 2020 end-page: 442 ident: CR14 article-title: Convergent antibody responses to SARS-CoV-2 in convalescent individuals publication-title: Nature doi: 10.1038/s41586-020-2456-9 – volume: 597 start-page: 97 year: 2021 end-page: 102 ident: CR3 article-title: SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape publication-title: Nature doi: 10.1038/s41586-021-03807-6 – volume: 184 start-page: 1804 year: 2021 end-page: 1820 ident: CR23 article-title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection publication-title: Cell doi: 10.1016/j.cell.2021.02.026 – volume: 8 year: 2018 ident: CR53 article-title: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis publication-title: Sci. Rep. doi: 10.1038/s41598-018-34171-7 – volume: 366 start-page: 8 year: 2011 end-page: 19 ident: CR55 article-title: A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2010.12.016 – volume: 369 start-page: 1501 year: 2020 end-page: 1505 ident: CR11 article-title: Structure-based design of prefusion-stabilized SARS-CoV-2 spikes publication-title: Science doi: 10.1126/science.abd0826 – volume: 584 start-page: 443 year: 2020 end-page: 449 ident: CR15 article-title: Potently neutralizing and protective human antibodies against SARS-CoV-2 publication-title: Nature doi: 10.1038/s41586-020-2548-6 – volume: 21 start-page: 1327 year: 2020 end-page: 1335 ident: CR33 article-title: SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0778-2 – volume: 2 start-page: 100405 year: 2021 ident: CR48 article-title: Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2021.100405 – volume: 276 start-page: 307 year: 1997 end-page: 326 ident: CR63 article-title: Processing of X-ray diffraction data collected in oscillation mode publication-title: Methods Enzymol. doi: 10.1016/S0076-6879(97)76066-X – volume: 54 start-page: 2143 year: 2021 end-page: 2158 ident: CR25 article-title: Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy publication-title: Immunity doi: 10.1016/j.immuni.2021.08.015 – volume: 373 start-page: eabh1766 year: 2021 ident: CR40 article-title: Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants publication-title: Science doi: 10.1126/science.abh1766 – volume: 25 start-page: 1605 year: 2004 end-page: 1612 ident: CR66 article-title: UCSF Chimera—a visualization system for exploratory research and analysis publication-title: J. Comput. Chem. doi: 10.1002/jcc.20084 – volume: 292 start-page: 3900 year: 2017 end-page: 3908 ident: CR35 article-title: Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice publication-title: J. Biol. Chem. doi: 10.1074/jbc.M116.767749 – volume: 59 start-page: e0052721 year: 2021 ident: CR21 article-title: Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.00527-21 – volume: 14 start-page: 290 year: 2017 end-page: 296 ident: CR65 article-title: cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination publication-title: Nat. Methods doi: 10.1038/nmeth.4169 – volume: 325 start-page: 632 year: 2021 end-page: 644 ident: CR1 article-title: Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2021.0202 – volume: 386 start-page: 117 year: 2012 end-page: 123 ident: CR50 article-title: High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2012.09.007 – volume: 33 start-page: 108322 year: 2020 ident: CR54 article-title: Structure-based design with tag-based purification and in-process biotinylation enable streamlined development of SARS-CoV-2 spike molecular probes publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.108322 – volume: 40 start-page: 658 year: 2007 end-page: 674 ident: CR60 article-title: Phaser crystallographic software publication-title: J. Appl. Crystallogr. doi: 10.1107/S0021889807021206 – ident: CR28 – volume: 27 start-page: 717 year: 2021 end-page: 726 ident: CR9 article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies publication-title: Nat. Med. doi: 10.1038/s41591-021-01294-w – volume: 65 start-page: 567 year: 2009 end-page: 573 ident: CR62 article-title: Generalized X-ray and neutron crystallographic analysis: more accurate and complete structures for biological macromolecules publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444909011548 – volume: 31 start-page: 517 year: 2021 end-page: 525 ident: CR45 article-title: Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies publication-title: Cell Res. doi: 10.1038/s41422-021-00487-9 – volume: 53 start-page: 524 year: 2020 ident: 1068_CR47 publication-title: Immunity doi: 10.1016/j.immuni.2020.07.020 – volume: 180 start-page: 519 year: 2012 ident: 1068_CR64 publication-title: J. Struct. Biol. doi: 10.1016/j.jsb.2012.09.006 – volume: 14 start-page: 290 year: 2017 ident: 1068_CR65 publication-title: Nat. Methods doi: 10.1038/nmeth.4169 – volume: 13 start-page: eabf1906 year: 2021 ident: 1068_CR43 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.abf1906 – volume: 82 start-page: 12449 year: 2008 ident: 1068_CR51 publication-title: J. Virol. doi: 10.1128/JVI.01708-08 – volume: 369 start-page: 1119 year: 2020 ident: 1068_CR49 publication-title: Science doi: 10.1126/science.abd2321 – volume: 33 start-page: 108322 year: 2020 ident: 1068_CR54 publication-title: Cell Rep. doi: 10.1016/j.celrep.2020.108322 – volume: 596 start-page: 276 year: 2021 ident: 1068_CR10 publication-title: Nature doi: 10.1038/s41586-021-03777-9 – volume: 6 start-page: 1233 year: 2021 ident: 1068_CR4 publication-title: Nat. Microbiol. doi: 10.1038/s41564-021-00972-2 – volume: 371 start-page: 823 year: 2021 ident: 1068_CR46 publication-title: Science doi: 10.1126/science.abf4830 – volume: 29 start-page: 819 year: 2021 ident: 1068_CR8 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.03.005 – volume: 78 start-page: 10628 year: 2004 ident: 1068_CR52 publication-title: J. Virol. doi: 10.1128/JVI.78.19.10628-10635.2004 – volume: 369 start-page: 1014 year: 2020 ident: 1068_CR37 publication-title: Science doi: 10.1126/science.abd0831 – volume: 184 start-page: 1821 year: 2021 ident: 1068_CR42 publication-title: Cell doi: 10.1016/j.cell.2021.02.035 – volume: 54 start-page: 2143 year: 2021 ident: 1068_CR25 publication-title: Immunity doi: 10.1016/j.immuni.2021.08.015 – volume: 21 start-page: 1327 year: 2020 ident: 1068_CR33 publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0778-2 – volume: 385 start-page: 1184 year: 2021 ident: 1068_CR2 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2109682 – volume: 26 start-page: 228 year: 2020 ident: 1068_CR39 publication-title: Nat. Med. doi: 10.1038/s41591-019-0746-2 – volume: 8 year: 2018 ident: 1068_CR53 publication-title: Sci. Rep. doi: 10.1038/s41598-018-34171-7 – volume: 143 start-page: 13 year: 2014 ident: 1068_CR58 publication-title: Immunology doi: 10.1111/imm.12323 – volume: 29 start-page: 806 year: 2021 ident: 1068_CR31 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2021.04.005 – volume: 31 start-page: 597 year: 2021 ident: 1068_CR44 publication-title: Cell Res. doi: 10.1038/s41422-021-00497-7 – volume: 3 start-page: e237 year: 2006 ident: 1068_CR57 publication-title: PLoS Med. doi: 10.1371/journal.pmed.0030237 – volume: 373 start-page: eabh1766 year: 2021 ident: 1068_CR40 publication-title: Science doi: 10.1126/science.abh1766 – volume: 370 start-page: 950 year: 2020 ident: 1068_CR16 publication-title: Science doi: 10.1126/science.abe3354 – volume: 292 start-page: 3900 year: 2017 ident: 1068_CR35 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M116.767749 – volume: 325 start-page: 632 year: 2021 ident: 1068_CR1 publication-title: JAMA doi: 10.1001/jama.2021.0202 – volume: 366 start-page: 8 year: 2011 ident: 1068_CR55 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2010.12.016 – volume: 184 start-page: 2332 year: 2021 ident: 1068_CR7 publication-title: Cell doi: 10.1016/j.cell.2021.03.028 – volume: 369 start-page: 1010 year: 2020 ident: 1068_CR41 publication-title: Science doi: 10.1126/science.abd0827 – volume: 181 start-page: 271 year: 2020 ident: 1068_CR6 publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 184 start-page: 1804 year: 2021 ident: 1068_CR23 publication-title: Cell doi: 10.1016/j.cell.2021.02.026 – volume: 27 start-page: 717 year: 2021 ident: 1068_CR9 publication-title: Nat. Med. doi: 10.1038/s41591-021-01294-w – volume: 369 start-page: 956 year: 2020 ident: 1068_CR13 publication-title: Science doi: 10.1126/science.abc7520 – ident: 1068_CR28 doi: 10.1101/2020.03.15.992883 – volume: 10 year: 2019 ident: 1068_CR38 publication-title: Nat. Commun. doi: 10.1038/s41467-019-10897-4 – volume: 369 start-page: 1501 year: 2020 ident: 1068_CR11 publication-title: Science doi: 10.1126/science.abd0826 – volume: 369 start-page: 650 year: 2020 ident: 1068_CR26 publication-title: Science doi: 10.1126/science.abc6952 – volume: 103 start-page: 8060 year: 2006 ident: 1068_CR59 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0602606103 – volume: 218 start-page: e20201993 year: 2021 ident: 1068_CR24 publication-title: J. Exp. Med. doi: 10.1084/jem.20201993 – volume: 276 start-page: 307 year: 1997 ident: 1068_CR63 publication-title: Methods Enzymol. doi: 10.1016/S0076-6879(97)76066-X – volume: 368 start-page: 630 year: 2020 ident: 1068_CR32 publication-title: Science doi: 10.1126/science.abb7269 – ident: 1068_CR19 doi: 10.1101/2021.05.09.443331 – volume: 386 start-page: 117 year: 2012 ident: 1068_CR50 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2012.09.007 – volume: 588 start-page: 682 year: 2020 ident: 1068_CR29 publication-title: Nature doi: 10.1038/s41586-020-2852-1 – volume: 25 start-page: 1605 year: 2004 ident: 1068_CR66 publication-title: J. Comput. Chem. doi: 10.1002/jcc.20084 – volume: 182 start-page: 73 year: 2020 ident: 1068_CR17 publication-title: Cell doi: 10.1016/j.cell.2020.05.025 – volume: 40 start-page: 658 year: 2007 ident: 1068_CR60 publication-title: J. Appl. Crystallogr. doi: 10.1107/S0021889807021206 – volume: 184 start-page: 2316 year: 2021 ident: 1068_CR22 publication-title: Cell doi: 10.1016/j.cell.2021.03.029 – volume: 36 start-page: 109450 year: 2021 ident: 1068_CR5 publication-title: Cell Rep. doi: 10.1016/j.celrep.2021.109450 – volume: 584 start-page: 115 year: 2020 ident: 1068_CR12 publication-title: Nature doi: 10.1038/s41586-020-2380-z – volume: 584 start-page: 450 year: 2020 ident: 1068_CR20 publication-title: Nature doi: 10.1038/s41586-020-2571-7 – volume: 31 start-page: 517 year: 2021 ident: 1068_CR45 publication-title: Cell Res. doi: 10.1038/s41422-021-00487-9 – volume: 372 start-page: 1108 year: 2021 ident: 1068_CR27 publication-title: Science doi: 10.1126/science.abg5268 – volume: 184 start-page: 2183 year: 2021 ident: 1068_CR30 publication-title: Cell doi: 10.1016/j.cell.2021.02.032 – volume: 584 start-page: 437 year: 2020 ident: 1068_CR14 publication-title: Nature doi: 10.1038/s41586-020-2456-9 – volume: 217 start-page: e20201181 year: 2020 ident: 1068_CR67 publication-title: J. Exp. Med. doi: 10.1084/jem.20201181 – volume: 9 start-page: e61312 year: 2020 ident: 1068_CR36 publication-title: Elife doi: 10.7554/eLife.61312 – volume: 597 start-page: 97 year: 2021 ident: 1068_CR3 publication-title: Nature doi: 10.1038/s41586-021-03807-6 – volume: 11 year: 2020 ident: 1068_CR34 publication-title: Nat. Commun. doi: 10.1038/s41467-020-19891-7 – volume: 65 start-page: 567 year: 2009 ident: 1068_CR62 publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444909011548 – volume: 584 start-page: 443 year: 2020 ident: 1068_CR15 publication-title: Nature doi: 10.1038/s41586-020-2548-6 – ident: 1068_CR18 doi: 10.1101/2021.03.24.436523 – volume: 59 start-page: e0052721 year: 2021 ident: 1068_CR21 publication-title: J. Clin. Microbiol. doi: 10.1128/JCM.00527-21 – volume: 60 start-page: 2126 year: 2004 ident: 1068_CR61 publication-title: Acta Crystallogr. D Biol. Crystallogr. doi: 10.1107/S0907444904019158 – volume: 2 start-page: 100405 year: 2021 ident: 1068_CR48 publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2021.100405 – volume: 473 start-page: 112630 year: 2019 ident: 1068_CR56 publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2019.07.002 |
| SSID | ssj0014764 |
| Score | 2.5521495 |
| Snippet | Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic... AbstractPrevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require... |
| SourceID | pubmedcentral osti proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1503 |
| SubjectTerms | 60 APPLIED LIFE SCIENCES 631/250/2499 631/250/255/2514 692/420/2780/2152/2153/1291 ACE2 Amino Acid Sequence Angiotensin Angiotensin-converting enzyme 2 Animals antibodies Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - immunology Antibodies, Monoclonal - metabolism Antibodies, Neutralizing - chemistry Antibodies, Neutralizing - immunology Antibodies, Neutralizing - metabolism Antibodies, Viral - immunology Antibodies, Viral - metabolism antimicrobial responses Binding Sites - genetics Biomedical and Life Sciences Biomedicine Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - metabolism COVID-19 - prevention & control Disease Models, Animal Dosage and administration Dose-Response Relationship, Drug Drug therapy, Combination Epitope Mapping Epitopes - chemistry Epitopes - immunology Epitopes - metabolism Humans Immunology Inactivation Infectious Diseases Methods Mice, Transgenic Monoclonal antibodies Neutralization Neutralization Tests Peptidyl-dipeptidase A Protein Binding Protein Conformation SARS-CoV-2 - genetics SARS-CoV-2 - immunology SARS-CoV-2 - metabolism Sequence Homology, Amino Acid Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology Spike Glycoprotein, Coronavirus - metabolism Spike protein Survival Analysis viral infection |
| SummonAdditionalLinks | – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fb9MwELZGEYgXBONXWEEGIfEA1hLHcezHqmIaiPGwMrQ3K3YcqDQSRNqi7q_nzkmDAgOJx8qX1Padz_fFd58JeSGc8xAZFywWtmSiqiwrZCWZlRn8KERaKiwUPvkgj8_Eu_PsfI_wXS1MSNoPlJbBTe-yww5b2Gh0zDChAFGMYpfXyHWkbkfANZfz4eRA5IEyCrYlzbiOVV8oE6fqineMNqPeJU8aWFtXxZt_pk3-dnYatqSjO-R2H0vSWdf7u2TP1_vkRne75Haf3Dzpz83vka_vmx-sbFpPlzXdLDcN7fkZQCu0qEta-3X45NEVZdIi9JcuZqcLNm8-MU43gKkxZYbaLQXLbdwFhvDw7Gppm3JLYRoBY3ef_-6Ts6M3H-fHrL9ogTkp1YpxrzWXTnrQnLO-qFzObYY8Pom2pdeJja2OS1Ep7lIprPZVBWEHgB_unAaM-4BM6qb2jwgFsK0yJVOBRP2FT5QSgN2rpKh4nJdaRSTZzbhxPQs5XoZxYcJpeKpMpyUDWjJBS-YyIq-GZ751HBz_lH6OijRIblFj9sznYt225u3i1MykEloAQBMRedkLVQ38vSv6YgQYBPJhjSSnI0lYfW7UfID2YiBeQdJdh9lJbmXAUeY8g9FOd2Zket_QGkSQeQ6eMIvIs6EZ34v5brVv1iCDl7lCMBznEXnYWd0w9FQgxs14RPKRPQ4CyBg-bqmXXwJzuAK0CTFZRF7vLPdXt_4-o4__T_yA3OK4xkLOz5RMVt_X_glEbiv7NCzVnyTNO7A priority: 102 providerName: Springer Nature |
| Title | Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations |
| URI | https://link.springer.com/article/10.1038/s41590-021-01068-z https://www.ncbi.nlm.nih.gov/pubmed/34716452 https://www.proquest.com/docview/2605770175 https://www.proquest.com/docview/2590085107 https://www.osti.gov/servlets/purl/1837258 https://pubmed.ncbi.nlm.nih.gov/PMC8642242 |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELegE4gXBANGWJkMQuIBrOXDSewn1FarBmIVahnqmxU7DlQaySBtUffXc5e4ncLHXlKlvrSx72zfzz7_jpBX3BgLnnHGfK5zxotCsywpEqaTGG4yHuUCDwqfTZLTc_5hHs_dglvtwiq3Y2IzUOeVwTXyY_S70xTsJ353-YNh1ijcXXUpNG6TPaQuQ6tO5zvAFfC0oY-CKUqyUPrCHZrxI3Fcw8QlfYYBCoiKBLvqTExueO5V0M_-5Xv-HUL5xz5qMz2NH5D7zq-kg9YQHpJbttwnd9pMk5t9cvfM7aE_It8_Vr9YXtWWLkq6Xqwr6rgaQEM0K3Na2lWz_NEe0KRZ8750NpjO2Kj6wkK6BnyN4TNUbyg0S2Uu0J2HZ5cLXeUbCg0KeLtdCnxMzscnn0enzCVdYCZJxJKFVsowMYkFLRpts8KkoY6R0yeQOrcy0L6Wfs4LEZoo4VraogClABAKjZGAd5-QXlmV9imhALxFLJKII2l_ZgMhOOD4IsiK0E9zKTwSbFtcGcdIjokxLlSzMx4J1WpJgZZUoyV15ZE3u2cuWz6OG6VfoiIVEl2UGEnzNVvVtXo_m6pBIrjkANa4R147oaKCvzeZO5gAlUBurI5kvyMJPdF0ig_RXhT4LkjAazBSySwVDJppGENt-1szUm6cqNW1VXvkxa4Yfxdj30pbrUAGE7uCY-ynHjlorW5X9Ygj3o1Dj6Qde9wJIHt4t6RcfGtYxAUgT_DPPPJ2a7nXr_X_Fn12cy0Oyb0Q-1QT79MnveXPlX0OXttSHzVdE65iFByRvcF4OJzA5_Bk8mkK346S0W-OTEIu |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BpFXF4QjFtYAYNAPIC1xHES5wGhqjC1rN3Duk17M7HjQKWRDNJ26j6Kb-ScJO0ULnvbY-STxPa52-dCyCthjAXLOGGu0CkTWaZZEmYh02EAD4nwU4mJwuO9cHAoPh8Hxxvk1yoXBsMqVzKxEtRpYfCMfBvt7igC-gk-nP5g2DUKb1dXLTRqsti1yzNw2cr3w4-A39ec73w66A9Y01WAmTCUM8ZtHPPQhBamabRNMhNxHWDRGi_WqY097erYTUUmufFDoWObZfBXsPS5MTE4dPDda-S68IE1MTO9vw4p8URUlasClRgzHruySdJxfbldgqKMXYYBEeiFSXbeUoSNOugUwNf_snX_Dtn84962Uoc7d8mdxo6lvZrw7pENm2-SG3Vny-UmuTlu7uzvk--j4oylRWnpNKeL6aKgTW0IoAia5CnN7bw6bqkTQmlSzZdOevsT1i-OGKcL8OcxXIfqJQU0FOYE3Qd4dzbVRbqkgEDw7-ujxwfk8ErQ8ZB08iK3jwkFR18GMvQFNglIrCelsJpnXpJxN0pj6RBvtePKNBXQsRHHiapu4n2paiwpwJKqsKTOHfJ2_c5pXf_jUuiXiEiFhTVyjNz5mszLUg0n-6oXShELcA6FQ940QFkBvzdJkwgBi8BaXC3IbgsSON-0hreQXhTYSljw12BklJkpENIRD2C13RUZqUYuleqCixzyYj2M38VYu9wWc4DBRrJgiLuRQx7VVLdeui_Qvw64Q6IWPa4BsFp5eySffquqlkvwdMEedMi7FeVeTOv_O_rk8lU8J7cGB-ORGg33drfIbY78VcUadUln9nNun4LFONPPKjal5MtVy4XfSel62w |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGERMvCMZXWAGDQDyA1cRxEucBoaqjWtmH0MbQ3kzsOFBpJIO0nbo_jb-Ou3x0Ch9722PlS2rnPnxn3_2OkBfCGAueccJcoVMmskyzJMxCpsMAfiTCTyUWCu_th9tH4sNxcLxGfrW1MJhW2drEylCnhcEz8gH63VEE8hMMsiYt4uPW-N3pD4YdpPCmtW2nUYvIjl2eQfhWvp1sAa9fcj5-_2m0zZoOA8yEoZwxbuOYhya0MGWjbZKZiOsAAWy8WKc29rSrYzcVmeTGD4WObZbBDMDr58bEENzBe6-R65EfSdQxOVqll3giqqCrYHuMGY9d2RTsuL4clLBpxi7D5AiMyCQ772yKzdbQK0DH_-X3_p2--ccdbrU1jm-TW41PS4e1EN4hazbfIDfqLpfLDbK-19zf3yXfd4szlhalpdOcLqaLgjY4ESAdNMlTmtt5dfRSF4fSpJovPRweHLJR8ZlxuoDYHlN3qF5SYENhTjCUgGdnU12kSwrMhFi_Poa8R46uhB33SS8vcvuQUAj6ZSBDX2DDgMR6UgqreeYlGXejNJYO8dovrkyDho5NOU5UdSvvS1VzSQGXVMUlde6Q16tnTmsskEupnyMjFYJs5CiuX5N5WarJ4YEahlLEAgJF4ZBXDVFWwN-bpCmKgEUgLleHst-hBCtgOsObKC8K_CYE_zWYJWVmCgx2xANYbb8VI9XYqFJdaJRDnq2G8b2Yd5fbYg402FQWnHI3csiDWupWS_cFxtoBd0jUkccVASKXd0fy6bcKwVxC1Au-oUPetJJ7Ma3_f9FHl6_iKVkHi6B2J_s7m-QmR_Wq0o76pDf7ObePwXmc6SeVllLy5arNwm8_4X8R |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low-dose+in+vivo+protection+and+neutralization+across+SARS-CoV-2+variants+by+monoclonal+antibody+combinations&rft.jtitle=Nature+immunology&rft.au=Dussupt+Vincent&rft.au=Sankhala%2C+Rajeshwer+S&rft.au=Mendez-Rivera+Letzibeth&rft.au=Townsley%2C+Samantha+M&rft.date=2021-12-01&rft.pub=Nature+Publishing+Group&rft.issn=1529-2908&rft.eissn=1529-2916&rft.volume=22&rft.issue=12&rft.spage=1503&rft.epage=1514&rft_id=info:doi/10.1038%2Fs41590-021-01068-z&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1529-2908&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1529-2908&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1529-2908&client=summon |